Early antiretroviral therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy : evidence from the Children with HIV Early antiretroviral therapy (CHER) Study.

SUNScholar Research Repository

Show simple item record

dc.contributor.author Hainline, Clotilde
dc.contributor.author Taliep, Reghana
dc.contributor.author Sorour, Gill
dc.contributor.author Nachman, Sharon
dc.contributor.author Rabie, Helena
dc.contributor.author Dobbels, Els
dc.contributor.author Janse van Rensburg, Anita
dc.contributor.author Cornell, Morna
dc.contributor.author Violari, Avy
dc.contributor.author Madhi, Shabir A.
dc.contributor.author Cotton, Mark F.
dc.date.accessioned 2011-12-14T13:44:45Z
dc.date.available 2011-12-14T13:44:45Z
dc.date.issued 2011-10
dc.identifier.citation Hainline, C. et al 2011. Early antiretroviral therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy : evidence from the Children with HIV Early Antiretroviral therapy (CHER) study. BMC Research Notes. 4(1):448-151. en_ZA
dc.identifier.issn http://dx.doi.org/10.1186/1756-0500-4-448
dc.identifier.uri http://hdl.handle.net/10019.1/18172
dc.description The original publication is available at http://www.biomedcentral.com/1756-0500/4/448
dc.description.abstract Abstract Background Although otorrhea occurs commonly in HIV-infected infants, there are few data. We compared the incidence of otorrhea in infants receiving early vs deferred ART in the Children with HIV Early Antiretroviral (CHER) trial. Infants aged 6 to 12 weeks of age with confirmed HIV infection and a CD4 percentage greater than or equal to 25% were randomized to early or deferred ART at two sites in South Africa. Medical records from one study site were reviewed for otorrhea. Findings Data were reviewed from the start of the trial in July 2005 until 20 June 2007, when the Data Safety Monitoring Board recommended that randomization to the deferred arm should stop and that all infants in this arm be reviewed for commencing antiretroviral therapy. Infants entered the study at a median of 7.4 weeks of age. Eleven of 38 (29%) on deferred therapy and 7 of 75 (9%) in the early-therapy group developed otorrhea (risk ratio 3.1, 95% confidence interval (CI) 1.31-7.36; p = 0.01). Conclusions Early initiation of antiretroviral therapy is associated with significantly less otorrhea than when a deferred strategy is followed. Trial registration NCT00102960. ClinicalTrials.Gov en_ZA
dc.format.extent 4 p.
dc.language.iso en_ZA en_ZA
dc.subject HIV-positive children -- Antiretroviral treatment -- Otitis media en_ZA
dc.subject HIV-positive children and deafness -- Developing countries -- Research en_ZA
dc.subject Hearing impaired children -- Diagnosis -- Developing countries en_ZA
dc.title Early antiretroviral therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy : evidence from the Children with HIV Early antiretroviral therapy (CHER) Study. en_ZA
dc.type Article en_ZA
dc.date.updated 2011-11-19T06:18:47Z
dc.description.version Peer Reviewed en_ZA
dc.language.rfc3066 en
dc.rights.holder Hainline et al.; licensee BioMed Central Ltd. en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record